Takeda has reported favourable interim results from a Phase III clinical trial of TAK-755 (recombinant ADAMTS13) for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,